EDITORIAL SECTION

  • STRATEGY

    Smarter Pharma

    Quality management systems QMS are the backbone of pharmaceutical manufacturing ensuring safe products

  • EXPERT Talk

    Compliance to Competitive Advantage in Pharma Supply

    Compliance gets you through an audit Resilience gets medicines to patients on the day something unexpected happens The DSCSAs enhanced requirements took effect November but real interoperability required three more rounds of accommodation phased implementation with the smalldispenser

KNOWLEDGE BANK

TOP ARTICLES

press releases Read more...

Syndax’s Revuforj® (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases

Syndax Pharmaceuticals a commercialstage biopharmaceutical company advancing innovative cancer therapies today announced that Revuforj revumenib has been recognized as the Best Product for RareOrphan Diseases of by The Galien Foundation The Galien Foundation fosters

Massive Bio and Global Leadership in Oncology & Wellness (GLOW) Announce Partnership to Expand Access to Clinical Trial Information for Patients and Caregivers

Massive Bio an agentic AI and realworld data RWD company advancing oncology drug development commercialization and access to precision medicine today announced a partnership with Global Leadership in Oncology Wellness GLOW a c nonprofit dedicated to bridging the gap between patients

INOVIO Announces FDA Accelerated Approval of VOCERYQ™, an Immunotherapy to Reduce the Frequency of Surgery in Adults with Recurrent Respiratory Papillomatosis (RRP)

INOVIO a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPVrelated diseases cancer and infectious diseases today announced that the US Food and Drug Administration FDA has granted accelerated approval for VOCERYQ doruxapapogene ral...

Helsinn announces UK MHRA approval of AKYNZEO® Oral Suspension

Helsinn Healthcare SA a global pharmaceutical group focused on supporting patients with cancer and chronic diseases today announced that the UK Medicines and Healthcare products Regulatory Agency MHRA has granted approval for the oral suspension formulation of AKYNZEO netupitantpalonosetron for the...

02 - 04

Nov 2026

Pharma Forum EMEA 2026

Dom Pedro Lisboa Hotel, Lisbon...

02 - 04

Nov 2026

Cancer R&D 2026

Houston, TX, USA

03 - 05

Nov 2026

10th Dermatology Drug Development

Boston, Massachusetts at The C...

03 - 04

Nov 2026

PDA Aseptic Processing of Biopharma Conference

Sheraton Grand Incheon Hotel,...

04 - 05

Nov 2026

Advanced Therapies USA

Hynes Convention Center, Bosto...

05 - 05

Nov 2026

PDA Contamination Control Strategy Workshop

Sheraton Grand Incheon Hotel,...

09 - 11

Nov 2026

11th Microbiome Movement USA Summit

The Colonnade Hotel, Boston, M...

10 - 11

Nov 2026

Extractables & Leachables Europe

Parkhotel Schӧnbrunn, Vienna,...

LATEST NEWS Read more...

UroGen Announces First Patient Dosed in Phase 1 Trial of UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer

UroGen Pharma Ltd a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers today announced that the first patient was dosed with UGN a nextgeneration investigational oncolytic virus The Phase trial will evaluate the safety tolera...

Graviton BioScience and CinRx Pharma Form CinRock Pharma to Advance ROCK2-Targeted Therapies for Cardiovascular Disease

Graviton BioScience Corporation Graviton and CinRx Pharma CinRx today announced the formation of CinRock Pharma CinRock a jointly governed biopharmaceutical company established to accelerate the development of novel ROCKtargeted therapies for patients with cardiovascular diseases

Pretzel Therapeutics Receives UK Regulatory Authorization to Advance PX578 Into Clinical Development in Patients for the Treatment of POLG-Mediated Primary Mitochondrial Disorders

Pretzel Therapeutics Inc a clinicalstage biotechnology company advancing a new class of medicines designed to restore mitochondrial function improve cellular energetics and impede disease progression across a range of neurological and rare diseases today announced that the Medicines and Healthcare p...

TME Pharma Signs Binding Exclusive Negotiation Agreement with Japanese TMS Co., Ltd.

TME Pharma NV Euronext Growth Paris ALTME a biotechcompany with clinical assets for brain cancer and eye diseases is pleased to announce a significant next step in the strategic options for its leading oncology asset NOXA olaptesed pegol

Twist Bioscience Launches MRD Express with Rapid Turnaround Time

Twist Bioscience Corporation a midcap growth and value biotech company today launched Twist MRD Express custom panels manufactured at scale with a rapid turnaround time starting within one day Twist MRD Express custom panels enable cancer researchers to investigate tumorassociated genomic variants

Strand Therapeutics Doses First Patients with STX-003, a Systemic Programmable mRNA Therapy Designed for Tumor-Selective Activation

Strand Therapeutics a clinicalstage biotechnology company pioneering programmable mRNA therapeutics today announced that the first patients have been dosed in ASCENT the Phase clinical trial of STX STX is an intravenously delivered selfreplicating mRNA therapy designed